Neuraxpharm and mjn-neuro Advance Digital Epilepsy Care with Early-Warning Device
Neuraxpharm and mjn-neuro are preparing to launch EPISERAS, an AI-driven wearable designed to predict epileptic seizures in real time, marking one of the most significant advances in consumer-facing neurology devices in recent years. The companies announced plans to bring the digital health solution to market across Europe beginning in the second half of 2026, targeting patients with drug-resistant epilepsy who continue to face high risk of unpredictable, potentially dangerous episodes.
EPISERAS is built around a discreet earpiece sensor that continuously monitors brain activity, using machine-learning algorithms to detect electrical patterns that signal an elevated likelihood of a seizure. When the device identifies rising risk, it sends an alert to patients and caregivers minutes before the event. The early warning window is designed to allow patients to move to safety, notify family members, or avoid hazardous activities that can increase injury risk.
What You Need To Know
- Neuraxpharm and mjn-neuro will launch EPISERAS, an AI-powered wearable that predicts epileptic seizures in real time using a non-invasive earpiece sensor.
- The device alerts patients and caregivers minutes before a seizure and is supported by interim data from the ongoing SERAS-Home_RWD study.
- EPISERAS holds CE and UKCA Class IIa certification and will launch across Europe beginning in the second half of 2026.
- The collaboration strengthens Neuraxpharm’s digital health strategy while leveraging mjn-neuro’s decade of AI-driven neurotechnology development.
The technology is paired with a connected mobile application that collects, analyzes, and displays real-time seizure-risk data. For patients who often live with the stress of unpredictable episodes, the ability to track brain-activity trends offers a level of insight and autonomy rarely available outside of hospital-grade EEG systems. The companies note that this is the first digital health device designed for real-time early detection of seizures available for both home and ambulatory use.
The launch is supported by a growing body of clinical evidence. Interim results from the multicenter SERAS-Home_RWD real-world study, running across Spain, the United Kingdom, and Germany, are currently being prepared for publication. According to mjn-neuro, the company has spent more than a decade developing the technology and validating its performance across multiple clinical trials. The device already holds CE and UKCA certification as a Class IIa medical device, positioning it for broad adoption once commercialization begins.
The move represents a strategic expansion for Neuraxpharm from pharmacological CNS therapies into digital health and medical devices. The company already markets a broad portfolio of anti-epileptic formulations, but EPISERAS pushes its capabilities deeper into personalized, real-time neurological care. Executives say the addition of this non-invasive, technology-driven tool advances the company’s commitment to enhancing safety, autonomy, and quality of life for people living with epilepsy.
Neuraxpharm CEO Dr. Jörg-Thomas Dierks emphasized the shift toward a more holistic model of CNS care, integrating medication with digital solutions capable of supporting patients around the clock. His remarks highlight a broader trend in the sector, pharma companies increasingly see value in combining therapeutic expertise with digital tools that extend treatment impact beyond the clinic. For chronic neurological disorders, where symptoms can vary widely and unpredictably, digital augmentation is emerging as a meaningful differentiator in patient outcomes.
mjn-neuro co-founder and CEO David Blánquez framed the collaboration as the natural next step after years of research, clinical testing, and partnership-building. According to Blánquez, the company’s long-standing work in AI-driven neurotechnology has generated robust evidence supporting the device’s predictive capabilities. Joining forces with Neuraxpharm gives the technology a commercial pathway capable of reaching patients at scale.
The announcement also underscores the growing importance of digital solutions for drug-resistant epilepsy, a population that often cycles through multiple therapeutic regimens with limited success. For these patients, the ability to anticipate seizures by even a few minutes can reduce accidents, lower emergency-care reliance, and materially improve daily functioning. The companies aim to position EPISERAS as a complement to standard therapies rather than a replacement, expanding the ecosystem of support available to patients.
The upcoming European launch forms part of Neuraxpharm’s broader diversification strategy following its 2022 partnership with mjn-neuro, which marked its formal entry into wearable neurotechnology. With direct presence in more than 20 European countries and partners worldwide, Neuraxpharm has the infrastructure to scale device-based solutions alongside its CNS drug portfolio. The company views the EPISERAS project as a foundational step in building a cross-category CNS franchise that spans medications, medical devices, and algorithm-powered digital health platforms.
Suggested news
Philips Debuts AI DeviceGuide to Enhance Real-Time Navigation in Heart Valve Repair
mjn-neuro, founded in 2014 in Girona, has staked its mission on using artificial intelligence and sensor-based technology to improve quality of life for patients with neurological disorders. The EPISERAS device, originally developed as mjn-SERAS, has undergone several clinical assessments since 2018. The company continues to advance new applications of AI for additional neurological conditions, working closely with clinical and technical institutions to shape the next wave of patient-centric neurotech.
As the commercial launch approaches, the collaboration between Neuraxpharm and mjn-neuro highlights a growing convergence of pharma, medical devices, and algorithmic healthcare. With regulatory certifications in place, real-world evidence emerging, and increasing industry appetite for AI-based neurological tools, EPISERAS may represent a meaningful shift in how seizure risk is monitored and managed in everyday life. For patients who face the constant uncertainty of epileptic episodes, the promise of predictive alerts and continuous monitoring signals a step toward greater safety, stability, and independence.
For media inquiries or to share perspectives on access and evidence policy, email editor@synopulse.com.
